Related Experiment Video
Updated: Jul 10, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
Two-Dimensional-PAGE Coupled with nLC-MS/MS-Based Identification of Differentially Expressed Proteins and Tumorigenic
Madhuri Jayathirtha1, Taniya Jayaweera1, Danielle Whitham1
1Biochemistry & Proteomics Laboratories, Department of Chemistry and Biomolecular Science, Clarkson University, 8 Clarkson Avenue, Potsdam, NY 13699, USA.
Abstract:
The identification of new cancer-associated genes/proteins, the characterization of their expression variation, the interactomics-based assessment of differentially expressed genes/proteins (DEGs/DEPs), and understanding the tumorigenic pathways and biological processes involved in BC genesis and progression are necessary and possible by the rapid and recent advances in bioinformatics and molecular profiling strategies. Taking into account the opinion of other authors, as well as based on our own team's in vitro studies, we suggest that the human jumping translocation breakpoint (hJTB) protein might be considered as a tumor biomarker for BC and should be studied as a target for BC therapy. In this study, we identify DEPs, carcinogenic pathways, and biological processes associated with JTB silencing, using 2D-PAGE coupled with nano-liquid chromatography tandem mass spectrometry (nLC-MS/MS) proteomics applied to a MCF7 breast cancer cell line, for complementing and completing our previous results based on SDS-PAGE, as well as in-solution proteomics of MCF7 cells transfected for JTB downregulation. The functions of significant DEPs are analyzed using GSEA and KEGG analyses. Almost all DEPs exert pro-tumorigenic effects in the JTBlow condition, sustaining the tumor suppressive function of JTB. Thus, the identified DEPs are involved in several signaling and metabolic pathways that play pro-tumorigenic roles: EMT, ERK/MAPK, PI3K/AKT, Wnt/β-catenin, mTOR, C-MYC, NF-κB, IFN-γ and IFN-α responses, UPR, and glycolysis/gluconeogenesis. These pathways sustain cancer cell growth, adhesion, survival, proliferation, invasion, metastasis, resistance to apoptosis, tight junctions and cytoskeleton reorganization, the maintenance of stemness, metabolic reprogramming, survival in a hostile environment, and sustain a poor clinical outcome. In conclusion, JTB silencing might increase the neoplastic phenotype and behavior of the MCF7 BC cell line. The data is available via ProteomeXchange with the identifier PXD046265.
Insights
The human jumping translocation breakpoint (hJTB) protein may serve as a breast cancer (BC) biomarker and therapeutic target. Silencing hJTB in MCF7 cells promoted pro-tumorigenic pathways, indicating its tumor-suppressive role.
Area of Science:
- Proteomics
- Cancer Biology
- Bioinformatics
Background:
- Advances in bioinformatics and molecular profiling enable identification of cancer-associated genes and pathways.
- The human jumping translocation breakpoint (hJTB) protein is proposed as a potential breast cancer (BC) biomarker and therapeutic target.
Purpose of the Study:
- To identify differentially expressed proteins (DEPs), carcinogenic pathways, and biological processes linked to JTB silencing in MCF7 cells.
- To further characterize the tumor-suppressive function of hJTB in breast cancer.
Main Methods:
- Proteomic analysis using 2D-PAGE and nano-liquid chromatography tandem mass spectrometry (nLC-MS/MS).
- Gene Set Enrichment Analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses for functional annotation of DEPs.
- Utilized MCF7 breast cancer cell line with downregulated JTB expression.
Main Results:
- JTB silencing led to the identification of numerous DEPs.
- These DEPs are implicated in pro-tumorigenic pathways including EMT, MAPK, PI3K/AKT, Wnt/β-catenin, mTOR, C-MYC, NF-κB, IFN responses, UPR, and glycolysis.
- The identified pathways support cancer hallmarks like growth, invasion, metastasis, stemness, and metabolic reprogramming.
Conclusions:
- JTB silencing enhances the neoplastic phenotype and behavior in MCF7 breast cancer cells.
- hJTB protein demonstrates tumor-suppressive functions.
- The findings support hJTB as a potential biomarker and therapeutic target for breast cancer.

